LRATD2

Across TCGA pan-cancer cohorts, LRATD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRATD2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LRATD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRATD2 expression acts as an unfavorable survival marker.

HNSC, LUAD, and COAD are the cancer types where LRATD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.169	0.710	.008	21	view →
LUAD	OS	Median	All	0.238	0.697	.015	16	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
GBM	OS	Median	All	0.089	0.413	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LRATD2–HNSC (OS)

Open the HNSC breakdown →